Introduction {#Sec1}
============

Attention deficit hyperactivity disorder (ADHD) is the most commonly diagnosed neurobehavioural disorder in childhood, affecting over 5% of children worldwide \[[@CR33]\]. Although there are differences between United States and European diagnostic criteria \[[@CR6]\], according to both the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV-TR) and the International Classification of Diseases (tenth edition, ICD-10), ADHD (or hyperkinetic disorder \[HKD\] according to ICD-10) is characterised by inappropriate levels of inattention, hyperactivity and impulsivity, which constitute the so-called ADHD core symptoms. These are often accompanied by comorbid symptoms, such as aggressive behaviour, depressive mood, anxiety and tics, by learning difficulties \[[@CR11]\], and by impairment of social functioning \[[@CR15], [@CR29]\]. ADHD symptoms are known to decline with age, and approximately half of those who had ADHD in childhood no longer meet the full diagnostic criteria for the disorder when they reach adulthood; however, up to 50% of childhood ADHD cases show continued clinically significant symptoms during adolescence and adult life, which can cause serious impairments in everyday life and increase the risk for drug dependence, depression and anxiety disorder \[[@CR1], [@CR17]\].

For decades, ADHD has been treated with stimulant medications, which in most cases produce a rapid and dramatic improvement in ADHD symptoms and in the behaviour of affected children \[[@CR6]\]. The use of stimulants for the management of ADHD has caused increasing public concern that it might predispose children to substance abuse as adolescents or adults. However, several studies have been conducted to address this issue, and there is no consistent evidence that stimulant treatment in childhood or during high school leads to a higher risk of drug use and addiction \[[@CR5]\]. Methylphenidate (MPH) is the most commonly prescribed stimulant for children with ADHD. It is believed to inhibit the reuptake of dopamine and noradrenaline into the presynaptic neuron, increasing their concentration in the extra-neuronal space and therefore enhancing neurotransmission \[[@CR3]\]. MPH is mainly metabolised by de-esterification into ritalinic acid, which is pharmacologically inactive; this results in a short half-life of 2.0--3.0 h and a short duration of action. The maximum plasma concentration (*C*~max~) of MPH, and consequently its maximum effect, is reached 1.5--2.0 h after dosing \[[@CR31]\].

Conventional, immediate-release (IR) MPH formulations have been used since the 1960s for the treatment of ADHD. Due to the short duration of action, MPH-IR needs to be administered repeatedly during the day to maintain effectiveness, 2--3 daily doses being required for most children \[[@CR29]\]. Multiple dosing can be problematic, as it can cause adherence issues and complications related to privacy, stigmatisation by classmates, potential abuse and accountability of the school administration \[[@CR25]\]. To overcome these problems, new long-acting formulations of MPH have been developed recently that combine IR and modified-release (MR) components \[[@CR20], [@CR32]\]. These MPH-MR formulations provide a rapid onset of therapeutic effect, while having a sufficient duration to eliminate the need for additional doses; furthermore, they have a biphasic plasma concentration profile that avoids acute tolerance.

Equasym XL^®^[1](#Fn1){ref-type="fn"} (Shire Pharmaceuticals Ireland Limited, Ireland) is a combination of MPH-IR and MR that uses a multi-particulate bead delivery system (Diffucaps^®^ technology, Eurand Pharmaceuticals, USA); each Equasym XL^®^ capsule contains 30% MPH-IR-coated beads and 70% MPH-MR-coated beads. Equasym XL^®^ produces an initial fast increase in MPH plasma concentration followed by a second increase after approximately 3 h, and therapeutic plasma concentration is maintained for about 8 h \[[@CR40], [@CR44]\]. Equasym XL^®^ has a good safety profile and is effective in controlling ADHD symptoms in children aged 6 years and older throughout a period consistent with the school day and homework time, depending on the length of the school day \[[@CR23]\]; it has been proven as effective as MPH-IR given twice daily \[[@CR19]\].

Open-label studies can provide valuable data on therapeutic effects by reflecting the real-life setting better than controlled clinical trials \[[@CR39]\]. Although clinical effectiveness of Equasym XL^®^ has also been shown in an open-label study \[[@CR12]\], no observational study has yet investigated the effectiveness of this MPH formulation using a structured combination of physician, teacher and parent ratings, as has been done for another MPH-MR formulation, Concerta ^®^ (Janssen-Cilag, High Wycombe, UK), in both European \[[@CR24], [@CR35]\] and Korean \[[@CR26]\] populations. The OBSEER (OBservation of Safety and Effectiveness of Equasym XL^®^ in Routine care) study was a non-controlled, non-interventional, post-marketing surveillance study conducted in Germany, designed to gain new insights into the effectiveness and safety of treatment with Equasym XL^®^ under routine care conditions. The study included children diagnosed with ADHD or HKD---either previously untreated or treated with different MPH formulations, other drugs or non-pharmaceutical therapies---for whom therapy with Equasym XL^®^ was already planned by the attending physician. The observation period for each patient was 6--12 weeks after the first use of Equasym XL^®^, and effectiveness and safety were assessed by physicians, parents and teachers.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

The study included male and female patients aged 6--17 years with a confirmed diagnosis of ADHD according to DSM-IV-TR (diagnostic codes 314.00 or 314.01) \[[@CR2]\] or HKD according to ICD-10 (diagnostic codes F90.0, F90.1 or F90.8) \[[@CR46]\], for whom therapy with Equasym XL^®^ (10/20/30 mg once daily) was already intended by the attending physician. Medication with long-acting MPH had to be indicated, and patients had to be attending school. Exclusion criteria included contraindications according to the summary of product characteristics and the presence of a mental handicap.

Study design {#Sec4}
------------

This was a non-interventional, non-controlled, multicentre, prospective, observational, post-marketing surveillance study conducted in 169 centres in Germany in accordance with local regulations and under the therapeutic responsibility of the attending physicians; ethics or institutional review board approval was not required for this study. Written informed consent was obtained from parents.

Physicians (specialists in paediatrics and/or child and adolescent psychiatry) were asked to select appropriate patients for whom therapy with Equasym XL^®^ was indicated. The required examinations were recorded at baseline (Visit 1), at a follow-up visit 1--3 weeks after the first use of Equasym XL^®^ (Visit 2) and at a final visit 6--12 weeks after the first use of Equasym XL^®^ (Visit 3). The information collected at Visit 1 included general data for the patient (sex, age, height, body weight, type of school and class), oral history of ADHD (duration, diagnosis in therapy-naïve patients according to the diagnostic checklist for HKD \[DCL-ADHD\] \[[@CR14]\], timing of severe ADHD symptoms, current ADHD treatment including dose and administration mode), previous pharmaceutical and non-pharmaceutical treatment of ADHD, concomitant diseases and medications, rationale for Equasym XL^®^ treatment in therapy-naïve patients and for switching therapy in previously treated patients, and details of the planned treatment with Equasym XL^®^. The study started on 2 November 2006; inclusion of patients concluded on 28 February 2007, and observation was completed on 27 December 2007.

Outcome measures {#Sec5}
----------------

Effectiveness was assessed by physicians using the clinical global impression severity (CGI-S) and Improvement (CGI-I) scales to rate ADHD core symptoms (inattention, hyperactivity and impulsivity) and disease-associated problems (aggressive behaviour, depressive mood, anxiety, tics and learning difficulties). CGI-S and CGI-I scores were recorded at each study visit. Categories for evaluation of CGI-S were as follows: 0 = normal; 1 = mild; 2 = moderate; 3 = severe. Categories for CGI-I during treatment, compared with the conditions before treatment with Equasym XL^®^, were as follows: −3 = very strongly worsened; −2 = strongly worsened; −1 = slightly worsened; 0 = unchanged, +1 = slightly improved; +2 = strongly improved; +3 = very strongly improved.

Teachers and parents completed the German ADHD Symptom Checklist (Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, FBB-ADHD) \[[@CR9], [@CR16]\] for each visit. FBB-ADHD is part of the German Diagnostic System for Mental Disorders in Children and Adolescents (DISYPS-II) \[[@CR13]\] and assesses the diagnostic criteria for ADHD according to DSM-IV-TR and for HKD according to ICD-10. The presence of 20 symptom items is rated on a scale ranging from 0 = not at all to 3 = very much, with higher scores indicating more severe symptoms. Nine symptom items are combined into a subscale assessing *inattention*, and 11 items are combined to assess *hyperactivity and impulsivity*; the total symptom score (ADHD total) covers all 20 symptom items. In addition, four items evaluate functional impairment with respect to school performance, relationship towards adults and children, and the subjective level of suffering (*functional impairment* subscale), and six items assess competences regarding attentive, reflexive and enduring behaviour (*attention*-*reflexivity* subscale). Scale scores represent the sum of the individual item scores divided by the number of items in each respective scale. The reliability and validity of the scale scores in parent and teacher ratings have been established in several studies \[[@CR8], [@CR13], [@CR16]\].

Teachers and parents also assessed ADHD symptoms and other externalising problems for each visit using the Day Profile of ADHD Symptoms (DAYAS) \[[@CR7]\]. The day profile of ADHD assessment is a new rating scale that assesses the daily profile of ADHD externalising symptoms from early morning until bedtime. The rating scale evaluates six items: (1) hyperactivity, (2) inattention, (3) impulsivity, (4) oppositional behaviour, (5) aggressive behaviour and temper tantrums and (6) a global rating of problem behaviour. The teacher version of the questionnaire (DAYAS-T) considers the first and second part of the morning at school (in Germany, children usually visit school only in the morning), while the parent version (DAYAS-P) considers four daily periods: early morning (before school), early afternoon until 4.00 pm, late afternoon until 7.00 pm and evening. Parents and teachers rate the items in each period on a four-point scale using the following values: 0 = not at all; 1 = just a little; 2 = pretty much; 3 = very much. The total score ('overall assessment') is the sum of the six item scores per time period divided by the number of items; in addition, the first three items are combined into the subscale '*ADHD symptoms*', and items 4 and 5 are combined into the subscale '*oppositional defiant disorder symptoms (ODD)*'. Ratings were conducted during the week preceding each assessment point (Visit 1, Visit 2 and Visit 3) and cover the typical behaviour of the child at different times of the day during that week. The reliability and validity of both the parent and the teacher versions of DAYAS have been established in several studies \[[@CR7]\].

Parents were also asked to complete the Strengths and Difficulties Questionnaire (SDQ-P) at baseline. SDQ is a brief behavioural screening questionnaire \[[@CR21]\], covering five scales: *emotional symptoms, hyperactivity, conduct problems, peer relationship problems* and *pro*-*social behaviour*. Scores were calculated for each subscale and were combined into an overall difficulties score as the sum of the four problem scales (i.e. excluding pro-social behaviour). Each scale was classified as normal, borderline or abnormal according to the thresholds established by Woerner et al. \[[@CR45]\] and Rothenberger et al. \[[@CR38]\] based on German population norms.

Adverse events {#Sec6}
--------------

Adverse events (AEs) were evaluated by the treating physician at each study visit, coded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 11.1 and classified into AEs and serious AEs. Physicians were also asked to record whether the AE occurred during previous treatment or while receiving Equasym XL^®^. Criteria of seriousness included occurrences leading to death, life-threatening conditions, hospitalisation or prolongation of hospitalisation, persistent injury/disability, incapacity for work, medically significant conditions and congenital abnormalities/birth defects.

Statistical analysis {#Sec7}
--------------------

The study planned to recruit a representative sample of 1,000 patients from 200 physicians, aiming for five patients per participating physician. This sample size was calculated to allow detection of any rare adverse drug reactions, with a power of 86% for an event with a probability of 0.2, and 63% for an event with a probability of 0.1%.

Absolute, relative and adjusted relative frequencies (i.e. omitting patients with missing data) were calculated. Multiple entries were possible for some items and were counted; therefore, the sum of relative frequencies could exceed 100%. The number of patients giving multiple replies was recorded in each case. To assess the effects over time on the outcome variables, repeated measures analyses of variance were conducted post hoc using multivariate analysis of variance (MANOVA), and effect sizes \[[@CR28], [@CR37]\] were calculated using Cohen's *d* \[[@CR10]\] for dependent samples, by dividing the difference between the means of Visit 1 and Visit 3 with a variable including the pooled standard deviations (SD) for Visits 1 and 3, and the bivariate correlation (r) between the two visits, as follows:$$\documentclass[12pt]{minimal}
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In order to calculate (post hoc) the normalisation rates for ADHD symptoms and functional impairment, a cut-off of 1 was defined on the ADHD total score and the functional impairment score obtained at Visit 3 on the FBB-ADHD scale (both parent- and teacher-rated). The same cut-off was used in the Multimodal Treatment study of ADHD (MTA) study on similar rating scales assessing ADHD symptoms as defined by DSM-IV \[[@CR41]\]; this cut-off was based on the ICD-10/DSM-IV criteria, which state that low severity of the specified behaviours (i.e. in the range from 0 = not at all to 1 = just a little on the FBB-ADHD scale) would not be sufficient to qualify them as symptoms of ADHD or ODD. In addition, norms for the FBB-ADHD parent-rated scores show that approximately 75--80% of school-age children manifest a total score of 1 or lower \[[@CR13]\].

Results {#Sec8}
=======

In total, 852 patients were recruited to the study, of whom 822 were considered evaluable; 30 patients were excluded from the analysis because of invalid data. Of the 822 evaluable patients, 777 completed all three planned visits. The number of patients documented at each visit, and data on the termination of treatment are presented in Fig. [1](#Fig1){ref-type="fig"}. The most frequent reasons for early discontinuation were lack of effectiveness (47 patients, 5.72%) and AEs (26 patients, 3.16%). The mean duration of treatment was 2.26 months, ranging from 5 days to over 12 months; overall, the duration of treatment was greater than 138 patient-years.Fig. 1Patient flow through the study (intent-to-treat population)

Patient characteristics {#Sec9}
-----------------------

Baseline patient demographics, ADHD diagnosis and the most frequent concomitant diseases are presented in Table [1](#Tab1){ref-type="table"}. More boys than girls were included in the study, and the mean age was 10.04 years, with no difference between boys and girls; the most common age was 9 years (16.71%). The majority of children (58.09%) attended primary school, most frequently third grade (8- to 9-year-olds). Most patients had a disturbance of activity and attention (ICD code F90.0), which is similar to ADHD combined type according to DSM-IV, followed by hyperkinetic conduct disorder (F90.1) and other HKD (F90.8). Hyperkinetic conduct disorder was more frequent in boys, and other HKDs were less frequent in patients aged 11 and under (5.94% versus 12.08%), particularly in boys. The time when ADHD was most impairing (counting multiple responses) was the school morning (81.10%), followed by early afternoon (69.34%), late afternoon (51.06%), early morning (43.55%) and evening (33.29%), according to physician ratings based on parent information.Table 1Baseline demographics and disease characteristicsTotalMaleFemaleBaseline demographics (*N* = 822) Patients, *n* (%)^a^816 (100)663 (81.25)153 (18.75) Age, years (mean \[SD\])^b^10.04 (2.47)10.06 (2.47)9.94 (2.49) Height, cm (mean \[SD\])^c^143.75 (15.10)144.01 (15.37)142.54 (13.90) Weight, kg (mean \[SD\])^d^37.98 (13.60)38.18 (13.41)37.08 (14.46) BMI, kg/m^2^ (mean \[SD\])^e^17.91 (3.41)17.92 (3.27)17.83 (3.97)ADHD diagnosis, *n* (%)*N* = 776^f^*N* = 634*N* = 142 F90.0: disturbance of activity/attention430 (55.41)345 (54.42)85 (59.86) F90.1: hyperkinetic conduct disorder282 (36.34)246 (38.80)36 (25.35) F90.8: other hyperkinetic disorders64 (8.25)43 (6.78)21 (14.79)*ADHD* attention deficit hyperactivity disorder, *BMI* body mass index, *SD* standard deviation; ^a^ *N* = 816 patients; ^b^ *N* = 808; ^c^ *N* = 764; ^d^ *N* = 786; ^e^ *N* = 758; ^f^ ADHD diagnosis is not specified for 46 patients

A total of 574 (69.83%) children had been treated previously with other MPH formulations, such as MPH-IR (most often Medikinet^®^, Medice, Germany) once or several times daily or MPH-MR (most often Medikinet^®^ XL, Medice, Germany) once daily, while 40 (4.87%) children had received a different pharmacological therapy, such as atomoxetine or amphetamine. A total of 208 (25.30%) children were treatment naïve. A total of 262 (31.87%) children had received non-pharmacological treatments, most commonly ergotherapy (physical activity and exercise) and behavioural therapy, in addition to pharmacological therapy or as the only treatment. The main reasons for switching therapy (counting multiple responses) were insufficient overall effectiveness of the previous treatment, including problems with effectiveness such as fluctuations or effects lasting too long (55.11%), too short an effect (50.86%), unwillingness to take a second dose at school (27.63%), problems remembering to take the second or third dose (20.09%), side-effects (8.95%), too late an onset of effect (5.02%) or other reasons (12.09%).

ADHD-CGI-S scores for core symptoms at baseline indicated that 17.17% of patients entering the study had mild symptoms, 59.14% had moderate symptoms, and 22.44% had severe symptoms. ADHD-associated problems were rated mild in 32.55% of patients, moderate in 48.08% and severe in 12.23%. Inattention was the most severe of the core symptoms, with a mean (SD) score of 2.1 (0.75), and learning difficulties were the most severe associated symptom, with a mean (SD) score of 1.83 (0.93).

The SDQ-P questionnaire (completed by parents) showed that 67.13% of patients had an overall difficulty score of abnormal, in contrast with the reference population expected value of 10% \[[@CR38]\]. The difference from the reference population was apparent in all SDQ subscales: *emotional symptoms* (35.73% abnormal, 15.79% borderline and 48.48% normal), *conduct problems* (42.30% abnormal, 15.67% borderline and 42.02% normal), *hyperactivity* (57.20% abnormal, 14.54% borderline and 28.25% normal) and *peer relationship problems* (35.60% abnormal, 14.13% borderline and 50.28% normal). The difference was less pronounced only in *pro*-*social behaviour* (14.27% abnormal, 14.40% borderline and 71.33% normal).

Administration of Equasym XL^®^ {#Sec10}
-------------------------------

Dosing data are presented in Fig. [2](#Fig2){ref-type="fig"}. The daily dose of Equasym XL^®^ administered during the study ranged from 10 mg to 120 mg; the maximum recommended daily dose (60 mg/day) was exceeded in six patients. As expected, the daily MPH dosage during previous treatment was substantially lower for patients receiving MPH-IR once daily compared with those receiving of MPH-IR administered several times per day or MPH-MR.Fig. 2Previous treatment dose by body weight at baseline and Equasym XL^®^ dose by body weight prescribed at Visit 1, Visit 2 and Visit 3, by prior treatment subgroup. MPH-MR, modified-release methylphenidate; MPH-IR, immediate-release methylphenidate; *SE* standard error

On average, at Visit 1, the physician prescribed Equasym XL^®^ at a higher dosage than prior medication in the group previously treated with once-daily MPH-IR, at a similar dosage in the group previously treated with repeated MPH-IR, and at a lower dosage in the group previously treated with an alternative MPH-MR formulation. In the subgroup with no previous medication, the mean prescribed dosage of Equasym XL^®^ was lower than all the other subgroups. Dosages slightly increased from Visit 1 to Visit 3, indicating that the physician prescribed Equasym XL^®^ according to recommended clinical practice, i.e. starting with a lower dose and subsequently titrating up according to the needs of the patient.

Effectiveness {#Sec11}
-------------

Statistical analyses of effectiveness outcomes are summarised in Table [2](#Tab2){ref-type="table"}. For all outcome measures, a statistically significant decrease was found in ADHD symptoms, ODD symptoms and associated functional impairment, as well as an increase in attention-reflexivity as rated by parents, teachers and clinicians. These results remain statistically significant after Bonferroni correction for multiple testing, and effect sizes vary from a small effect (Cohen's *d* = 0.30) to a large effect (Cohen's *d* = 1.17); the largest change was observed for CGI-S (Cohen's *d* = 1.17).Table 2Statistical analysis summary of CGI-S, parent and teacher FBB-ADHD and DAYAS scoresScales*N*Assessment pointMain effect MANOVA and effect sizeVisit 1Visit 2Visit 3F\*Cohen's *d* (Visit 1--Visit 3)MeanSDMeanSDMeanSDClinical rating Global impression (CGI-S)6342.020.671.430.691.070.65447.51.17Parent ratings (FBB-ADHD) Inattention7011.870.631.350.601.210.58334.50.95 Hyperactivity/impulsivity6991.430.791.020.700.860.65256.40.85 ADHD total6991.630.621.170.591.020.56356.21.00 Functional impairment6981.830.731.380.731.150.71238.20.82 Attention-reflexivity6990.880.621.140.641.220.6587.80.49Teacher ratings (FBB-ADHD) Inattention5221.600.731.270.671.110.66123.50.69 Hyperactivity/impulsivity5211.070.850.810.730.680.6673.30.53 ADHD total5201.310.711.020.630.880.59110.90.65 Functional impairment5191.500.891.170.800.980.7698.80.62 Attention-reflexivity5110.980.631.160.641.240.6344.50.41Day profile-parent (DAYAS-P) Total score  Morning before school6821.370.771.080.731.020.7296.10.51  Afternoon6681.510.681.090.630.940.61209.40.78  Late afternoon6851.610.681.300.641.200.64125.10.59  Evening6831.480.741.290.721.200.7256.40.40 ADHD symptoms  Morning before school6811.380.811.090.781.020.7880.30.47  Afternoon6671.550.711.110.660.940.64217.00.77  Late afternoon6821.650.701.350.651.250.67103.30.54  Evening6791.500.771.320.761.230.7641.70.35 ODD symptoms  Morning before school6781.280.881.010.790.950.7959.80.40  Afternoon6601.350.821.010.730.890.71102.50.55  Late afternoon6791.490.831.200.771.110.7684.30.48  Evening6741.410.871.200.831.130.7945.50.36Day profile-teacher (DAYAS-T) Total score  Morning first half5151.070.740.840.640.730.6057.30.47  Morning second half4941.420.811.100.720.960.6995.30.61 ADHD symptoms  Morning first half5151.160.780.910.670.780.6363.20.50  Morning second half4941.600.851.210.761.060.72111.60.66 ODD symptoms  Morning first half5140.830.810.670.690.600.6624.40.30  Morning second half4921.090.910.870.810.740.7642.60.41*ADHD* attention deficit hyperactivity disorder, *CGI-S* clinical global impression severity, *DAYAS* day profile of ADHD assessment, *DAYAS-P/T* DAYAS-parent/teacher, *FBB-ADHD* Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, *M* mean, *MANOVA* multivariate analysis of variance, *ODD* oppositional defiant disorder, *SD* standard deviation\* All effects are statistically significant at *P* \< 0.001

According to CGI-I ratings, ADHD core symptoms improved during treatment with Equasym XL^®^ in 524/692 (75.73%) patients, stayed unchanged in 123 (17.77%) and worsened in 45 (6.50%) (Fig. [3](#Fig3){ref-type="fig"}a). Similarly, ADHD-associated problems improved in 451/676 (66.71%) children, remained unchanged in 182 (26.92%) and worsened in 43 (6.37%) (Fig. [3](#Fig3){ref-type="fig"}b).Fig. 3CGI-I scores. **a** Rating of change of ADHD core symptoms between Visit 1 and Visit 3 (*n* = 692). **b** Rating of change of ADHD-associated problems between Visit 1 and Visit 3 (*n* = 676). ADHD, attention deficit hyperactivity disorder; CGI-I, clinical global impression improvement

The severity profile of core symptoms and associated problems at Visit 1 and at the last visit after Visit 1 (either Visit 2 or Visit 3), according to CGI-S ratings, is shown in Fig. [4](#Fig4){ref-type="fig"}: Improvement was observed in all symptoms and problems, with a particularly strong reduction in core symptoms and learning difficulties.Fig. 4CGI-S profile of ADHD core symptoms and associated problems at Visit 1 and at last visit. ADHD, attention deficit hyperactivity disorder; CGI-S, clinical global impression severity. Mean values: 0 = not at all; 1 = just a little; 2 = pretty much; 3 = very much

At the final examination after 6--12 weeks of treatment (Visit 3), physicians were asked to provide a global evaluation of the effectiveness of Equasym XL^®^ according to their medical judgement. This was collected for 721 children, and effectiveness was rated as very good in 255 patients (35.37%), good in 312 (43.27%), moderate in 108 (14.98%) and poor in 46 (6.38%).

Large reductions in ADHD symptoms were also found for parent-rated ADHD symptoms according to ICD-10/DSM-IV (Table [2](#Tab2){ref-type="table"}, FBB-ADHD, ADHD total: Cohen's *d* = 1.00), while the symptom reduction based on teacher ratings was in the moderate range (Table [2](#Tab2){ref-type="table"}, FBB-ADHD, ADHD total: Cohen's *d* = 0.65). Figure [5](#Fig5){ref-type="fig"} shows the scores on the FBB-ADHD scales at Visit 1 and last visit as rated by parents and teachers. Similar effects were found for the subscales of *hyperactivity/impulsivity* and *inattention*, and *functional impairment* was also reduced in both parent and teacher ratings; conversely, the competency scores of *attention*-*reflexivity* increased for both parents and teachers.Fig. 5FBB-ADHD scores at Visit 1 and at last visit, as assessed by teachers and parents. FBB-ADHD, Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörung. Mean values: 0 = not at all; 1 = just a little; 2 = pretty much; 3 = very much

Table [3](#Tab3){ref-type="table"} shows the percentage of patients below a score of 1 at Visit 1, Visit 2 and Visit 3 in the ADHD *total* and *functional impairment* FBB-ADHD subscales. The percentage of patients in the normal range for ADHD symptoms increased from 16.31% in parent ratings and 36.73% in teacher ratings at Visit 1---54.22 and 64.62% at Visit 3, respectively. Similarly, the percentage of patients without *functional impairment* increased from 10.89% (parents) and 26.01% (teachers) to 35.96 and 45.86%, respectively.Table 3Percentage of patients below a score of 1 in the ADHD total and functional impairment ratings at Visit 1, Visit 2 and Visit 3 (FBB-ADHD)Rating*N* (total)Visit 1Visit 2Visit 3*n*%*n*%*n*%Parents ADHD total69911416.3130243.2037954.22 Functional impairment6987610.8918526.5025135.96Teachers ADHD total52019136.7327753.2633664.62 Functional impairment51913526.0119637.7623845.86*ADHD* attention deficit hyperactivity disorder, *FBB-ADHD* Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörung

Teachers and parents also assessed the daily profile of ADHD symptoms (items 1--3), ODD symptoms (items 4--5) and problematic behaviour (item 6) using the DAYAS questionnaire. For all periods of the day, a statistically significant improvement in ADHD symptoms, ODD symptoms and overall rating was observed (Table [2](#Tab2){ref-type="table"}). Figure [6](#Fig6){ref-type="fig"} shows the changes in ADHD symptoms from Visit 1 to Visit 3 in the different periods of the day, in terms of effect sizes as calculated in Table [2](#Tab2){ref-type="table"}. The strongest symptom changes were observed in the second half of the school morning (rated by teachers) and in the early afternoon (rated by parents), while changes in the first half of the school morning (teachers) and in the late afternoon (parents) were somewhat lower. The smallest changes were observed in the early morning and in the evening at home (both rated by parents).Fig. 6Effect sizes (Cohen's *d*) for the reduction in total DAYAS scores between Visit 1 and Visit 3 throughout the day. DAYAS, day profile of attention deficit hyperactivity disorder assessment

Safety {#Sec12}
------

Overall, 313 AEs were recorded in 209/822 patients (25.43%). For 93 AEs (mainly tics) in 88 patients, the physician failed to specify whether the AE occurred under previous treatment or current treatment; these events are included here to provide a conservative analysis. One patient had six AEs, three patients had five AEs, four patients had four AEs, 16 patients had three AEs, 43 patients had two AEs, and 142 patients had only one AE. The most frequent AEs, by MedDRA 11.1 preferred code, were psychiatric disorders (19.83% of all patients), metabolism and nutrition disorders (2.43%) and gastrointestinal disorders (2.19%). A list of AEs showing a frequency higher than 0.30% is presented in Table [4](#Tab4){ref-type="table"}. Most AEs were mild or moderate in intensity, although 47 events in 29 patients were considered severe. Severity was unrecorded for 148 AEs (120 patients).Table 4AEs, by MedDRA 11.1 preferred code (*n* = 822)Adverse event (MedDRA 11.1)Number of AEsNumber of casesFrequency (%)Tic10610012.17Aggression32313.77Depressed mood13131.58Initial insomnia11111.34Headache1091.09Anorexia991.09Gastrointestinal pain991.09Nausea991.09Sleep disorder991.09Decreased appetite980.97Not evaluable760.73Depression440.49Onychophagia330.36Tremor330.36*AE* adverse event, *MedDRA* Medical Dictionary of Regulatory Activities

In total, 38 AEs in 21 patients were classified as serious (2.55%); no serious AE resulted in death. In 26 (3.16%) cases, treatment was discontinued as a result of AEs. At the end of the study, 104 events in 66 patients (8.03%) had resolved, 31 events in 25 patients (3.04%) were unresolved, and 25 events in 17 patients (2.07%) had not changed since onset; the clinical outcome of 14 AEs in 11 patients (1.34%) was unknown to the physician, and for 139 AEs in 116 patients (14.11%), there was no information about the outcome. No action was required for 83 AEs in 64 patients (7.79%), symptomatic therapy was prescribed for 30 AEs in 20 patients (2.43%), and the Equasym XL^®^ dose was reduced as a consequence of 13 AEs in 11 patients (1.34%); 6 AEs in 4 patients (0.49%) led to a temporary interruption of treatment, and 40 AEs in 26 patients (3.16%) led to treatment discontinuation. A total of 27 AEs in 18 patients (2.19%) were considered related to the study treatment, 48 AEs in 34 patients (4.14%) were considered likely to be treatment related, 70 AEs in 47 patients (5.72%) were considered possibly treatment related, and 25 AEs in 22 patients (2.68%) were considered unlikely to be related to treatment.

Physicians assessed the global tolerability of Equasym XL^®^ at the final examination at Visit 3. Tolerability was considered to be very good in 415/734 patients (56.54%), good in 270/734 (36.78%) patients, moderate in 33/734 (4.50%) patients and poor in 16/734 (2.18%) patients. No global assessment was provided for 88 patients.

Discussion {#Sec13}
==========

This large observational study used multiple outcomes and different raters to assess ADHD profile across the day in a natural setting and, to our knowledge, is the first such study. Results showed that Equasym XL^®^ was well tolerated and effective for the treatment of children and adolescents with ADHD in daily clinical practice conditions.

The efficacy and safety of this MPH-MR formulation had previously been assessed in three placebo-controlled clinical trials \[[@CR19], [@CR23], [@CR42]\] and in one 3-week post-marketing study \[[@CR12]\]. The population analysed in this study is similar in terms of demographics, ADHD diagnosis and severity of ADHD symptoms at baseline to those analysed in previous trials. However, the observational period of this post-marketing study is longer; the final examination was in fact carried out after 6--12 weeks of treatment, compared with 1--3 weeks in clinical trials. Also, the nature of this study is different to a clinical trial as it is an observation of real-life treatment providing a comprehensive assessment with ratings from physicians, parents and teachers. Compared with other observational trials of MPH-MR formulations \[[@CR12], [@CR18], [@CR24], [@CR26], [@CR35]\], the OBSEER study is the largest, and one of the most rigorous, to date.

Three-quarters (75.73%) of patients showed improvements in ADHD core symptoms on the CGI-I scale during treatment with Equasym XL^®^ compared with the prior treatment status (either receiving medication or not), and only 6.50% of patients had worsened scores. The rate of improvement was similar to that observed in the previous open-label Equasym XL^®^ trial (65% of patients had ratings of very much or much improved) \[[@CR12]\], although the criteria for efficacy were different. This is similar to results from a 6-month open-label study of the MPH transdermal system in adolescents, where 75.9% of patients were classed as 'very much improved' or 'much improved' on the CGI-I scale \[[@CR18]\]. In a 4-week, open-label study of Concerta in children (aged 6--13 years), CGI-I scores for ADHD symptoms were rated as improved for approximately 92% of patients \[[@CR26]\].

Results from FBB-ADHD ratings confirm the CGI-I/S findings. For the improvement in symptoms according to total FBB-ADHD scores from Visits 1 to 3, an effect size (Cohen's *d*) of 1.00 was calculated for parent ratings and 0.65 for teacher ratings. As nearly 70% of patients were already on medication at Visit 1, these effect sizes might be considered larger than expected. In one meta-analysis of randomised controlled trials, effect sizes (standardised mean difference) of between 0.6 and 1.0 were calculated for the effects of MPH-MR treatment versus placebo \[[@CR4]\]. Another meta-analysis of randomised controlled studies of short-acting MPH reported a standardised change score from pre- to post-assessment (mean weighted Cohen's *d*) of 1.53 (95% confidence intervals \[CI\]: 1.23--1.82) for parent ratings of ADHD symptoms and 1.83 (95% CI: 1.43--2.12) for teacher ratings \[[@CR43]\].

Furthermore, the percentage of patients in the OBSEER study in the normal range for ADHD total and functional impairment scores on the FBB-ADHD, as rated by parents and teachers, increased from Visit 1 to Visit 3, with 54--65 and 36--46% of patients in the normal range for symptoms and overall impairment, respectively. By comparison, in the randomised MTA study, the percentage of patients in the normal range after 14 months of treatment was 56% for the group receiving MPH-IR (medication management group), according to combined ratings of ADHD and ODD symptoms from parents and teachers \[[@CR41]\]. Thus, although cross-study comparisons must be treated with caution, particularly for studies with such different designs, results from this observational trial are comparable with those from randomised studies.

Similarly, ADHD-associated problems improved in two-thirds (66.71%) of patients and worsened in only 6.37%. In teacher and parent assessments, behaviour improved compared with baseline at all six measured time points across the day, in particular in the second half of the school morning and in the early afternoon. These peak effectiveness times coincided with the times of day patients reported as being most problematic at the beginning of the study and covered homework time. Moreover, this day profile in a real-life situation is consistent with the mean plasma concentration of Equasym XL^®^, which shows a peak 6 h after ingestion \[[@CR20]\]; it is also in line with the pharmacodynamic profile across the day in a laboratory classroom situation described in the COMACS study \[[@CR42]\], in which maximum effects were observed 1.5--6 h after administration.

AEs were recorded in one-quarter of patients, and the number and type of AEs were generally similar to prior Equasym XL^®^ clinical trials \[[@CR12], [@CR19], [@CR23]\]. However, comparison with other studies should be made with caution because the OBSEER study had a longer period of observation compared with clinical trials. Although the frequency of tics was over 12% in this study, it was similar to the frequency (13% \[teacher scores\] and 7% \[parent scores\]) reported for the Equasym XL^®^ arm of a previous randomised controlled 3-week trial that excluded patients with a history of tics \[[@CR23]\]. While early studies considered tics to be a contraindication to the use of stimulants for hyperactive syndromes \[[@CR27]\], more recent evidence suggests that while stimulants may worsen pre-existing tics \[[@CR30], [@CR34]\], there is no support for an increased risk of first-onset tics \[[@CR22], [@CR36]\]. As OBSEER was an observational study, patients with pre-existing tics were not excluded, neither were pre-existing and emergent tics differentiated, so conclusions regarding this issue are limited. The number of serious AEs was notably higher in this study; 38 serious AEs were in fact observed in 21 patients out of 822 (2.5%), compared with one serious AE in one patient out of 310 (0.3%) treated with Equasym XL^®^ in another observational study \[[@CR12]\], one serious AE in one patient out of 139 (0.7%) \[[@CR19]\] or no serious AEs out of 155 patients \[[@CR23]\] in the previous clinical trials. As noted earlier, this is possibly due to the longer period of observation and to the fact that for many AEs, it could not be excluded that they had already occurred under the previous medication. In addition, there was no global assessment of tolerability by physicians for 10.7% of patients, and being an observational study, there was little or no formal training of investigators for the assessment of seriousness of AEs, which might account for the difference in the number of serious AEs compared with previous trials.

There were several other limitations to this study. First, this was an open-label study without a control group; therefore, physicians and parents were not blinded to the study treatment or dose. Teachers were not formally informed of the change of treatment, and although they could have been told by parents or children, most were not aware. The lower effect sizes in teacher ratings may therefore be a more realistic picture of the real effects of Equasym XL^®^, without the expectation effects that may have influenced the ratings by parents and the physician, who were not satisfied with the prior medication or the untreated status. Secondly, due to the design of the study, the results for the previously treated group can only be generalised to a population in which a switch to Equasym XL^®^ is planned due to suboptimal effects of the prior medication. Distinct advantages of this study are the long period of observation and the use of multiple outcome measures with multiple informants. As it was an observational study, and no strict exclusion criteria were applied, this analysis describes the real population treated in clinical practice \[[@CR39]\].

In conclusion, this study confirmed the effectiveness of Equasym XL^®^ under the conditions of daily practice in which treatment with Equasym XL^®^ was planned, as the response to treatment was positive for the majority of patients; the improvements observed are particularly striking because most children had already been treated with different formulations of the same active substance. The frequency and nature of AEs observed here are consistent with earlier studies. These results also suggest that Equasym XL^®^ covers daily requirements effectively, in particular in the parts of the day when ADHD symptoms tend to be most impairing, possibly as a result of its 30:70 IR to MPH-MR content and/or its greater ease of administration.
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